Curative Biotechnology Inc Overview
Pro stress-test →Curative Biotechnology is a development-stage biomedical company focused on identifying, acquiring, and developing disease-modifying therapeutic drug candidates for rare diseases and conditions. The company's primary focus is degenerative eye diseases, leveraging an exclusive worldwide license from the National Eye Institute (NEI) at the National Institutes of Health (NIH) to develop novel treatments.
Strategic Profile
Pro stress-test →Curative's lead program centers on a topical metformin eye drop formulation for treating age-related macular degeneration (AMD), geographical atrophy, and other degenerative eye conditions. The company also maintains programs in infectious disease and neuro-oncology, with recent efforts toward OTCQB uplisting and capital structure strengthening through strategic initiatives.
Competitive Landscape
Pro stress-test →Curative competes within the rare disease and ophthalmic therapeutics sector against larger biotech companies with established pipelines such as Regeneron, Allergan (AbbVie), and academic/NIH-funded research initiatives. As a development-stage company, Curative's competitive advantage relies on its exclusive NIH license and novel approach rather than established market presence or manufacturing scale.
Industry Context
Curative Biotechnology Inc operates in Pharmaceuticals / Rare Disease Biotech / Ophthalmic Therapeutics.
Key facts
Headquarters: Boca Raton, Florida · Market cap: $8.81M